Related Experiment Video
Updated: Jul 24, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Juvenile idiopathic arthritis and its associated uveitis
Arash Maleki1,2,3, Priya D Patel2,3, C Steven Foster2,3,4
1Department of Ophthalmology, University of Florida, Gainesville, FL, USA.
Insights
Juvenile idiopathic arthritis (JIA) and its associated uveitis require lifelong monitoring and treatment. New biologic therapies show promise, but more research is needed for better outcomes in children and adults.
Area of Science:
- Pediatric Rheumatology
- Ophthalmology
Background:
- Juvenile idiopathic arthritis (JIA) is a leading chronic rheumatic condition in children.
- Uveitis is the most frequent extra-articular manifestation of JIA, posing a significant risk to vision.
Purpose of the Study:
- To review the epidemiology, risk factors, clinical presentation, diagnostics, treatments, and complications of JIA and JIA-associated uveitis.
- To discuss current and emerging therapeutic strategies, including conventional immunomodulatory therapy and biologic response modifiers.
- To examine the long-term disease course, functional outcomes, and quality of life for patients with JIA and associated uveitis.
Main Methods:
- Comprehensive literature review of JIA and JIA-associated uveitis.
- Analysis of epidemiological data, clinical findings, and treatment outcomes.
- Evaluation of immunomodulatory and biologic therapies.
Main Results:
- Biologic agents have improved outcomes for JIA and associated uveitis over the last 30 years.
- A substantial number of patients necessitate ongoing treatment into adulthood.
- Limited FDA-approved biologic options exist for JIA-associated uveitis.
Conclusions:
- Lifelong screening and monitoring are essential for patients with JIA and associated uveitis.
- Further randomized clinical trials are crucial to explore novel medications for JIA-associated uveitis.
- Enhanced therapeutic strategies are needed to improve long-term management and quality of life.
Introduction:
Juvenile idiopathic arthritis is the most common chronic rheumatologic disease in children. Uveitis is the most common extra-articular manifestation of JIA, and it can be a sight-threatening condition.
Areas Covered:
In this review article, we discussed epidemiology, risk factors, clinical presentation, supportive laboratory tests, treatment options, and complications of Juvenile idiopathic arthritis and Juvenile idiopathic arthritis associated uveitis. We covered conventional immunomodulatory therapy and biologic response modifiers agents for different types of Juvenile idiopathic arthritis and their associated uveitis. Finally, we discussed the course of disease, functional outcome, and the quality of life of Juvenile idiopathic arthritis and Juvenile idiopathic arthritis-associated uveitis.
Expert Opinion:
Although clinical outcomes of Juvenile idiopathic arthritis and its associated uveitis have been improved over the past three decades by biologic response modifier agents, a significant proportion of patients require active treatment into adult life therefore screening and monitoring of these patients is required during the patient's entire life. The limited number of food and drug administration approved biologic response modifier agents for the treatment of Juvenile idiopathic arthritis associated uveitis justify more randomized clinical trials with new medications in this field.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Nephrotic Syndrome II : Assessment and Medical Management
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Nephrotic Syndrome I : Introduction
Pericarditis I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

